Literature DB >> 29462119

Comparison of Methicillin-resistant Versus Susceptible Staphylococcus aureus Pediatric Osteomyelitis.

William T Davis1, Shawn R Gilbert1,2.   

Abstract

BACKGROUND: The incidence of methicillin-resistant Staphylococcus aureus (MRSA) pediatric osteomyelitis has risen and been associated with a more severe clinical course than methicillin-susceptible Staphylococcus aureus (MSSA) infections. National databases have been underutilized to describe these trends. We compared demographics, clinical course, and outcomes for patients with MRSA versus MSSA osteomyelitis.
METHODS: We queried the 2009 and 2012 Healthcare Cost and Utilization Project Kids Inpatient Database for discharge records with diagnosis codes for osteomyelitis and S. aureus. We explored demographics predicting MRSA and evaluated MRSA versus MSSA as predictors of clinical outcomes including surgery, sepsis, thrombophlebitis, length of stay, and total charges.
RESULTS: A total of 4214 discharge records were included. Of those, 2602 (61.7%) had MSSA and 1612 (38.3%) had MRSA infections. Patients at Southern and Midwestern hospitals were more likely to have MRSA than those at Northeastern hospitals. Medicaid patients' odds of MRSA were higher than those with private insurance, and black patients were more likely to have MRSA compared with white patients. MRSA patients were more likely to undergo multiple surgeries compared with MSSA patients and were more likely to have complications including severe sepsis, thrombophlebitis, and pulmonary embolism. Patients with MRSA had longer lengths of stay than those with MSSA and higher total charges after controlling for length of stay.
CONCLUSION: Review of a national database demonstrates MRSA is more prevalent in the South and Midwest regions and among black patients. MRSA patients have more surgeries, complications, and longer lengths of stay. LEVEL OF EVIDENCE: Level III.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29462119     DOI: 10.1097/BPO.0000000000001152

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  6 in total

1.  Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Qun Yan; Kerryl E Greenwood-Quaintance; Jayawant Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

2.  The Underlying Molecular Basis and Mechanisms of Venous Thrombosis in Patients with Osteomyelitis: A Data-Driven Analysis.

Authors:  Peisheng Chen; Yinhuan Liu; Xiaofeng Lin; Bin Yu; Bin Chen; Fengfei Lin
Journal:  Genet Res (Camb)       Date:  2022-06-06       Impact factor: 1.375

Review 3.  Acute infectious osteomyelitis in children: new treatment strategies for an old enemy.

Authors:  Sabrina Congedi; Chiara Minotti; Carlo Giaquinto; Liviana Da Dalt; Daniele Donà
Journal:  World J Pediatr       Date:  2020-05-11       Impact factor: 2.764

4.  Clinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections.

Authors:  Jumi Yi; James B Wood; C Buddy Creech; Derek Williams; Natalia Jimenez-Truque; Inci Yildirim; Bethany Sederdahl; Michael Daugherty; Laila Hussaini; Mohamed Munye; Kay M Tomashek; Christopher Focht; Nora Watson; Evan J Anderson; Isaac Thomsen
Journal:  J Pediatr       Date:  2021-03-24       Impact factor: 6.314

5.  Prediction of Adverse Outcomes in Pediatric Acute Hematogenous Osteomyelitis.

Authors:  Zaid Alhinai; Morvarid Elahi; Sangshin Park; Bill Foo; Brian Lee; Kimberle Chapin; Michael Koster; Pablo J Sánchez; Ian C Michelow
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

6.  Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Scott A Cunningham; Jayawant N Mandrekar; Bobbi S Pritt; Tiffany R Keepers; Alisa W Serio; Surya Chitra; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.